AIFM2 and prostate cancer: Multiple ferroptosis-related prognostic models in prostate cancer have identified elevated FSP1 expression as a critical marker predicting unfavorable outcomes, correlating closely with higher Gleason scores (≥8), shorter biochemical recurrence intervals, and increased propensity for castration-resistant progression [85,87].